KRMD Share Price Performance
US$4.32
1.96 (83.05%)
46.0% undervalued intrinsic discount
US$8.00
Fair Value
Price US$4.32
AnalystHighTarget US$8.00
AnalystLowTarget US$4.00
AnalystConsensusTarget US$6.25
Fair ValueUS$8.00
Share Pricen/a
KORU Medical Systems, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
KRMD Community Narratives
AN
Fair Value US$8 46.0% undervalued intrinsic discount
Prefilled Syringe Shift And Oncology Infusion Adoption Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$4 8.0% overvalued intrinsic discount
SCIg Therapy Adoption And Oncology Expansion Will Ultimately Disappoint Long-Term Expectations
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$6.25 30.9% undervalued intrinsic discount
Subcutaneous Therapy Expansion Will Support Long-Term Revenue Durability And Diversified Infusion Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Prefilled Syringe Shift And Oncology Infusion Adoption Will Transform Long Term Prospects
Catalysts About KORU Medical Systems KORU Medical Systems develops and supplies subcutaneous infusion systems and consumables used to deliver immunoglobulin and other specialty biologic drugs in home and clinic settings. What are the underlying business or industry changes driving this perspective?Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$8
46.0% undervalued intrinsic discount
Fair Value
Profit Margin
6.38%
Future PE
109.09x
Price in 2029
US$10
Subcutaneous Therapy Expansion Will Support Long-Term Revenue Durability And Diversified Infusion Opportunities
Catalysts About KORU Medical Systems KORU Medical Systems develops and commercializes subcutaneous infusion systems and related consumables for immunoglobulin and other specialty biologic therapies worldwide. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6.25
30.9% undervalued intrinsic discount
Fair Value
Profit Margin
2.93%
Future PE
200.65x
Price in 2028
US$7.81
SCIg Therapy Adoption And Oncology Expansion Will Ultimately Disappoint Long-Term Expectations
Catalysts About KORU Medical Systems KORU Medical Systems develops and commercializes subcutaneous drug delivery systems, focused on infusions for immunoglobulin therapies and other specialty biologics. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4
8.0% overvalued intrinsic discount
Fair Value
Profit Margin
4.99%
Future PE
77.88x
Price in 2028
US$5
Trending Discussion
Recently Updated Narratives
AN
Prefilled Syringe Shift And Oncology Infusion Adoption Will Transform Long Term Prospects
Fair Value: US$8 46.0% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Subcutaneous Therapy Expansion Will Support Long-Term Revenue Durability And Diversified Infusion Opportunities
Fair Value: US$6.25 30.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SCIg Therapy Adoption And Oncology Expansion Will Ultimately Disappoint Long-Term Expectations
Fair Value: US$4 8.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
KORU Medical Systems, Inc. Key Details
About KRMD
- Founded
- 1980
- Employees
- 73
- CEO
- WebsiteView website
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
